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Summary
Benign hereditary chorea (BHC) is an autosomal dom-
inant disorder characterized by an early-onset nonpro-
gressive chorea. The early onset and the benign course
distinguishes BHC from the more common Huntington
disease (HD). Previous studies on families with BHC
have shown that BHC and HD are not allelic. We studied
a large Dutch kindred with BHC and obtained strong
evidence for linkage between the disorder and markers
on chromosome 14q (maximum LOD score 6.32 at re-
combination fraction 0). The BHC locus in this family
was located between markers D14S49 and D14S1064,
a region spanning ∼20.6 cM that contains several in-
teresting candidate genes involved in the development
and/or maintenance of the CNS: glia maturation factor-
b, GTP cyclohydrolase 1 and the survival of motor
neurons (SMN)-interacting protein 1. The mapping of
the BHC locus to 14q is a first step toward identification
of the gene involved, which might, subsequently, shed
light on the pathogenesis of this and other choreatic
disorders.
Introduction
Choreatic disorders are common neurological entities
that can be either acquired or inherited. A well-known
familial entity is Huntington disease (HD [MIM
143100]), an autosomal dominant form of progressive
chorea associated with mood and personality changes,
usually presenting in adult life and leading to early death.
In contrast to HD, benign hereditary chorea (BHC [MIM
118700]) has its onset in childhood and is nonprogres-
sive. This autosomal-dominant disorder usually starts
before age 5 years, reaching its maximum severity be-
Received August 25, 1999; accepted for publication October 5,
1999; electronically published December 27, 1999.
Address for correspondence and reprints: Dr. Bert B. A. de Vries,
Department of Clinical Genetics, Erasmus University, P. O. Box 1738,
3000 DR, Rotterdam, The Netherlands. E-mail: devries@kgen.fgg
.eur.nl
q 2000 by The American Society of Human Genetics. All rights reserved.
0002-9297/2000/6601-0016$02.00
tween at age 10–20 years. Generally, BHC patients have
normal intelligence, and dementia, as in HD, is not seen.
The early onset of symptoms, frequently before 1 year
of age, suggests a developmental disturbance. In some
BHC families, the choreic movements tend to decrease
in adulthood. A nearly complete penetrance in males and
a 0.75 penetrance in females were reported by Harper
(1978). The disorder occurs less often than HD (Harper
1978).
Since the identification of BHC in 1966 (Haerer et al.
1966, 1967), more than 30 families have been reported
to have this disorder (reviewed by Bruyn and Myrian-
thopoulos [1986] and Wheeler et al. [1993]). The dis-
order demonstrates both intra- and interfamilial varia-
bility. Some BHC families show atypical additional
features, such as dysarthria and gait disturbances (Chun
et al. 1973), mental impairment (Leli et al. 1984), or
axial dystonia and progression in adulthood (Schady and
Meara 1988). The latter report could describe a variant
of the disorder, but might as well be an entirely separate
entity, considering the progressiveness of the chorea in
that family (Wheeler et al. 1993). Other variants have
been described as well, such as BHC associated with
sensorineural deafness (Damasio et al. 1977) and BHC
with intention tremor (Pincus and Chutorian 1967).
These studies also reflect the interfamilial variability. Al-
though treatment with haloperidol, chlorpromazine, and
prednisone led to improvement for some patients
(Wheeler et al. 1993), a general curative treatment is not
available. Besides HD, BCH should be differentiated
from a number of other diseases, such as familial cere-
bellar ataxia, Sydenham chorea, and Friedreich ataxia
(Bruyn and Myrianthopoulos 1986; Wheeler et al.
1993). However, the benign clinical course of the chorea
and the family history in BHC generally facilitate the
correct diagnosis.
In 1993, the gene for HD, IT15, was identified on
chromosome 4p16.3 (The Huntington’s Disease Collab-
orative Research Group 1993). The IT15 gene contains
a highly polymorphic CAG repeat at the 5′ end in the
range of 10–35 copies. In HD patients, the CAG repeat
is expanded beyond 36 repeats (The Huntington’s Dis-
ease Collaborative Research Group 1993; Kremer et al.
1994). Although an expanded CAG repeat in the 5′ end
of the IT15 gene has been found in one atypical BHC
family (MacMillan et al. 1993), several reports show
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that BHC is not allelic to HD (Quarrell et al. 1988;
Yapijakis et al. 1995; Hageman 1996). We performed a
genomewide linkage study in a large BHC family with
ataxia and found evidence for a gene defect responsible
for BHC localized on chromosome 14q.
Subjects, Material, and Methods
Subjects
Thirty-three relatives from a four-generation Dutch
family with BHC were included in the study. The ped-
igree is shown in figure 1. Informed consent was ob-
tained from each subject. The study was approved by
institutional review by the Medical Ethical Committee
of Erasmus University and University Hospital Dijkzigt,
Rotterdam. All individuals, except for spouses and sub-
ject III-14, were examined by a neurologist (W.F.M.A.)
and medical records from the past were reviewed, if
available. Children with obvious clinical features of
BHC were included in the study only after informed
consent was given by the parents. Apparently unaffected
children younger than 18 years of age were excluded
from the study because of nonpenetrance of the disorder
reported in other families. Blood samples were collected
from 30 individuals.
DNA Analysis
Genomic DNA was isolated from peripheral blood,
as described by Miller et al. (1988). Short-tandem-repeat
polymorphisms from the Marshfield screening set 6A
(see Electronic-Database section) were used for geno-
typing. Genomic DNA (25 ng) was amplified in 10-ml
PCR reactions containing GeneAmp PCR Gold Buffer,
1.5 mM MgCl2, 25 ng of fluorescent forward primer,
25-ng unlabeled reverse primer; and 0.4 U of AmpliTaq
Gold DNA polymerase. Initial denaturation was 15 min
at 957C, followed by 32 cycles of 30 s denaturation at
957C, 30 s annealing at 557C, and a 90 s extension at
727C. Reactions were prepared by using a Beckman Bio-
meck 2000 robot system and done in 384-well plates
covered with sealing lids (Costar 6557; 6555). Ampli-
fication was done by using a dual 384-well-equipped
GeneAmp PCR System 9700 (PE Biosystems). PCR
products were pooled and loaded on an ABI377 auto-
mated sequencer (filterset C; 5% denaturing FMC
LongRanger acrylamide gel) and data were analyzed by
using ABI GeneScan3.1 and ABI Genotyper2.1 software.
Binning of the alleles and preparation of prelinkage files
was done by using Linkage Designer 1.0 (Van Camp et
al. 1997).
Oligonucleotide primers were used to amplify the tri-
nucleotide repeat for HD, spinocerebellar ataxia 1
(SCA1), SCA2, Machado Joseph disease (SCA3), SCA6,
and dentatorubropallidoluysian atrophy (DRPLA) (Gel-
lera et al. 1996).
Linkage Analysis
Two-point linkage analysis was done by using the
MLINK and ILINK programs of the LINKAGE package
(version 5.1). Maximum LOD and location scores were
calculated for each marker by using two different models
because of uncertainty of penetrance values reported in
other families. In model 1, an “affected-only analysis,”
unaffected persons were typed as unknown. In model 2,
all available clinical diagnoses of pedigree members were
included, and 100% penetrance was assumed. For both
models, a gene frequency of 1:10,000, no phenocopies,
and equal allele frequencies of the genotyped markers
were used in the calculations. Changing allele frequen-
cies of the polymorphic markers did not significantly
alter the LOD and location scores.
Results
Clinical Analysis
The affected persons in the pedigree showed a gen-
erally mild neurological disorder with a benign course
(fig. 1). Clinical data are shown in table 1. During child-
hood, the affected subjects had considerable problems,
such as choreatic movements of the hands, feet, and
head, sometimes accompanied by a slight ataxia of gait.
No further abnormalities were found in the first three
generations, except for psychosis in subject III-14. Be-
cause of his psychosis, the latter patient was not avail-
able for physical examination; however, he was shown
to be affected by history. A mild pyramidal syndrome
was observed in the proband (subject IV-1). She had a
mild spastic-ataxic diplegia. Extensive studies in many
affected relatives excluded other known causes, and a
diagnosis of BHC was made. The course in this family
was benign. The luxury movements usually did not sub-
side completely, but they abated considerably by early
adulthood, as did the ataxia. Sydenham’s chorea had
been diagnosed in some children, but this diagnosis ev-
idently had to be revised because of the familial nature
of the affection. There was a suggestion of anticipation
in this family, because the children in the fourth gen-
eration were clearly more severely affected than their
parents and grandparents and showed cerebellar and
pyramidal signs in addition to the involuntary move-
ments. However, at this moment, the ultimate devel-
opment of these children is still unknown.
At age 3 mo, the proband (subject IV-1) was already
hyperkinetic, with superfluous movements of the ex-
tremities and later, the face. At a later age, her speech
was unclear. At age 2.5 years, an analysis of her devel-
opmental delay and deterioration of her walking ability
was done. She fell repeatedly and had uncoordinated
movements of the extremities, with a dysmetric gait and
a slight intention tremor. The legs were extended while
walking, with a tendency to go on tiptoes. Reflexes were
Figure 1 Pedigree of Dutch BHC family with haplotypes for chromosome 14q12–q22 markers (ordered from centromere to telomere). Blackened symbols represent affected subjects. Symbols
with N represent unaffected subjects. ? = diagnosis unknown. Bars next to haplotypes indicate a shared-risk haplotype. Blackened circles (•) indicate inconsistent genotype (subject IV-3).
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Table 1
Clinical Findings of BHC Family
SUBJECT
AGE
(YEARS)
CHOREATIC MOVEMENTS
ATAXIA
PYRAMIDAL
SIGNS
IMPROVEMENT
IN
ADOLESCENCEBy History By Examination
II-4 61 1 1 1/2 2 1
II-5 65 1 2 2 2 1
II-7 62 1 2 2 2 1
II-10 56 1 2 2 2 1
II-12 50 1(?) 2 2 2 1
II-14 53 1 2 2 2 1
III-2 33 1 1 1/2 2 1
III-4 29 1 1 1/2 2 1
III-5 28 1 2 2 2 1
III-6 28 1 1 2 2 1
III-7 27 1 1 2 2 1
III-8 29 1/2(?) 2 2 2 1
III-10 26 1 2 2 2 1
III-13 31 1 1 1/2 2 1
III-14 29 1
III-17 24 1 2 2 2 1
IV-1 4 1 1 1 1 NA
IV-2 5 1 1 1 ? NA
IV-3 3 2 2(?) 1 1 NA
Note.—The affected subjects are shown and subjects II-12, III-8, and IV-3, who are classified
as unknown (?). Subject III-14 was not available for neurological examination. NA = not available.
brisk and the plantar responses were extensor. The head
was titubating frequently. There were no signs of luxury
movements, and the fine motor skills were better pre-
served than the gross motor skills. Intellectual devel-
opment seemed to be normal without intellectual de-
cline. Magnetic resonance imaging (MRI) investigation
of the brain had normal findings. Other causes for cer-
ebellar and extrapyramidal syndromes at this age were
excluded. DNA studies for SCA (types 1, 2, 3, and 6),
HD, and DRPLA were normal (data not shown). At age
5 years, her gait problems were unchanged. She showed
choreatic movements in the arms.
A typical example of a patient now in his twenties is
III-6. He showed delayed motor development, walking
alone at age of 2 years. He remained clumsy, with a
walking pattern suggesting ataxia, without other signs
of ataxia. His speech was slightly dysarthric. At age 5
years, he developed involuntary movements later diag-
nosed as chorea. They increased in severity during the
next 2 years and then stabilized, interfering with his
school performance. Choreatic movements increased
with physical exertion. At age 12 years, the walking
pattern was no longer considered ataxic, and, a few years
later, the choreatic movements had almost completely
vanished. At age 19 years, his motor capabilities were
considered normal, and he was working as a metal as-
sembly worker. His brother, III-7, had similar symptoms,
signs, and clinical course.
Three relatives (II-12, III-8, IV-3) were classified as
unknown (table 1 and fig. 1). Sydenham’s chorea had
been diagnosed in childhood in subject II-12, but this
diagnosis evidently has to be revised, considering the
course of the affection and its familial nature. Subject
III-8 did not show abnormalities on physical examina-
tion and the history of choreatic movements was unclear.
He had problems with walking until age 18 years; how-
ever, these difficulties seemed more related to weakness
in the legs than to abnormal movements. Subject IV-3
had ataxic diplegia without obvious signs of chorea.
Seven relatives were unaffected, on the basis of history
as well as physical examination by a neurologist (W.F.
M.A.).
Linkage Analysis
Several candidate loci for trinucleotide-repeat elon-
gation—HD, SCA 1, SCA2, Machado Joseph disease
(SCA3), SCA6, and DRPLA—were tested on the pro-
band (subject IV-1). No repeat elongation beyond that
found in the general population was found (data not
shown).
To determine whether the BHC phenotype was linked
to the HD gene region, 10 polymorphic markers on the
short arm of chromosome 4 were subsequently tested.
Two different linkage models, as described earlier, were
used to demonstrate that none of the markers showed
evidence for linkage, making chromosome 4p an un-
likely site for BHC (data not shown).
Subsequently, a genomewide search with polymorphic
markers was started. A total of 95 markers were used
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Figure 2 Haplotype sharing of subjects of the Dutch BHC fam-
ily. Dark bars represent maximal extension of BHC “risk” haplotype
in each subject. Dotted lines delineate the maximal critical region of
20.6 cM from recombinational events. Chromosome 14q12–q22 link-
age map plus intermarker distances are indicated. A = affected; NA =
nonaffected; ? = diagnosis unknown.
until marker D14S306 showed a positive LOD score. A
maximum two-point LOD score of 4.20 was found by
using the affected-only analysis (model 1) and a score
of 6.32 by using model 2 (100% penetrance). Additional
markers flanking D14S306 were tested (table 2). The
order of all markers was taken from the Marshfield com-
prehensive linkage map chr.14 (see Electronic-Database
section). No recombination was observed between the
phenotype and D14S1049, D14S1014, D14S306,
D14S288, D14S984, and D14S747. The highest LOD
scores were obtained with markers D14S984 and
D14S306; LOD 6.32 at recombination fraction (v) 0 by
using model 2 (100% penetrance), indicating strong ev-
idence for linkage between these markers and the BHC
locus. The closest recombination events in affected per-
sons were seen between the phenotype and D14S49
proximal and D14S1064 distal (fig. 1 and fig. 2). Pair-
wise LOD scores were calculated for different values of
v for all markers by use of the two different models and
are summarized in table 2. Additional haplotype analysis
by using clinical diagnosis of all persons in the pedigree
did not reduce the genomic interval, so that the most
likely location of the BHC locus in this family is between
D14S49 and D14S1064, a region spanning ∼20.6 cM
(fig. 1 and fig. 2).
Discussion
BHC is one of the choreic disorders that should be
differentiated clinically from HD. In children with BHC,
the most characteristic presenting symptom is the motor
delay associated with the choreic movements. Later on
in childhood, their inability to write legibly hampers
schooling. A correct diagnosis at a young age will avoid
unnecessary investigations and enable the parents to be
reassured. Although the clinical signs in all patients in
this Dutch family with BHC ameliorate in adolescence,
a minority remained choreatic into adulthood. Several
patients had (minor) ataxia, two adult patients had psy-
chosis (one not shown in the pedigree), and a child had
pyramidal signs. These additional features suggest a
more general involvement of the brain than the basal
ganglia alone. The early onset of clinical features pre-
suppose a disturbance of development. The clinical
course with improvement in time is, to some extent,
similar in the patients of this family. However, some
adults still showed choreatic and/or slight ataxia, even
beyond age 60 years. The latter reflects the intrafamilial
variability, as has been reported in other families with
BHC (Bruyn and Myrianthopoulos 1986; Wheeler et al.
1993). Additional features also reported in other families
with BHC include dysathria and ataxia (Chun et al.
1973; Harper 1978; Schady and Meara 1988). Schady
and Meara (1988) reported a family with, in addition
to the dysarthria, elements of an axial dystonia. How-
ever, these symptoms were progressive in the latter fam-
ily, which is uncharacteristic for BHC and therefore
might indicate a different disorder. Also, other BHC fam-
ilies with additional manifestations have been reported,
suggesting clinical heterogeneity.
Several loci, such as the HD gene region, were ex-
cluded as the location of the BHC locus in this large
Dutch family. In addition, the SCA1, SCA2, SCA3,
SCA6, and DRPLA-related CAG-repeat elongations
were excluded. Subsequently, the BHC locus was located
on chromosome 14q12–22 in a 20.6-cM interval defined
by the markers D14S49 and D14S1064. This shows the
heterogeneity of genes and loci involved in the devel-
opment of movement disorders, and the changing effects
of some mutations over time: BHC ameliorates and HD
aggravates.
A candidate-gene search of this region identified large
numbers of expressed-sequence tags, most with un-
known function, and three interesting candidate genes
that are expressed in the nervous system. The first, the
glia maturation factor-b, is a small, 142-amino acid
polypeptide expressed in the brain of vertebrates (Kap-
lan et al. 1991). This endogenous brain protein is in-
volved in the differentiation, maintenance, and regen-
eration of the nervous system and expressed in neurons
as well as astrocytes (Wang et al. 1992). The protein’s
level increases slowly prenatally and plateaus shortly af-
ter birth, as studied in rat brain (Zaheer et al. 1993).
Because the clinical features in BHC patients appear be-
fore the first year, a disturbance in maturation of glia
cells might be part of the pathogenic process, although,
so far, no major cerebral abnormalities, as detectable by
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Table 2
Pairwise LOD Scores for Different Values of v between BHC and
Chromosome 14 Markers
MARKER
LOD SCORE AT v =
.00 .01 .05 .10 .20 .30 .40 v
Model 1a
D14S54 23.50 .16 1.31 1.61 1.55 1.16 .60 .14
D14S49 2.40 1.26 1.75 1.80 1.54 1.08 .50 .08
D14S1049 4.20 4.14 3.87 3.51 2.75 1.88 .91 .00
D14S1014 2.05 2.01 1.87 1.68 1.27 .82 .34 .00
D14S306 4.20 4.14 3.87 3.51 2.75 1.88 .91 .00
D14S288 3.30 3.24 3.01 2.71 2.07 1.36 .61 .00
D14S984 4.20 4.14 3.87 3.51 2.75 1.88 .91 .00
D14S747 2.56 2.51 2.34 2.10 1.60 1.05 .45 .00
D14S1064 2.40 .04 1.04 1.36 1.34 1.01 .53 .14
D14S980 22.04 20.49 0.06 .20 .19 .10 .03 .14
Model 2b
D14S54 2` .24 2.00 2.45 2.38 1.82 .97 .14
D14S49 2` .16 1.32 1.62 1.56 1.16 .56 .13
D14S1049 5.86 5.77 5.41 4.94 3.90 2.71 1.36 .00
D14S1014 2.36 2.32 2.16 1.95 1.49 .98 .41 .00
D14S306 6.32 6.23 5.83 5.31 4.19 2.91 1.47 .00
D14S288 4.53 4.45 4.15 3.75 2.90 1.96 .93 .00
D14S984 6.32 6.23 5.83 5.31 4.19 2.91 1.47 .00
D14S747 4.08 4.01 3.74 3.39 2.64 1.79 .85 .00
D14S1064 2` 1.64 2.72 2.90 2.58 1.89 .98 .10
D14S980 2` 2.93 2.22 .04 .19 .16 .08 .22
a Affected persons only.
b Affected and unaffected persons.
MRI studies, were found in BHC (Bruyn and Myrian-
thopoulos 1986; Wheeler et al. 1993). At a later patient
age, the delayed maturation might be (partially) over-
come by other factors consistent with the reduction of
symptoms. Another candidate is GTP cyclohydrolase 1
(GCH1). Mutations in GCH1 were found in hereditary
progressive dystonia with diurnal variation (HPD [MIM
128230]) (Ichinose et al. 1994). Remarkably, the course
of HPD and BHC is slightly similar, with onset in the
first decade, progression in the first two decades, and
amelioration, at a later age in BHC and subsided pro-
gression in HPD. However, HPD shows mainly dystonic
movements that increase during the day and are re-
sponsive to l-DOPA, suggesting that its pathogenesis is
restricted to the nigrostriatal dopaminergic system.
Moreover, in HPD a marked female predominance is
noted (Segawa et al. 1986), whereas in BHC the pene-
trance is reported to be lowered in females (Harper
1978) or similar between the sexes, as in the current
family (see following).
The survival of motor neurons (SMN)–interacting
protein 1 (SIP1), which is associated with the SMN gene
product (Liu et al. 1997), might be another candidate.
The SMN gene product is deleted or mutated in 98%
of the spinal muscular atrophy patients. SIP1 and SMN
forms a complex with spliceosomal small nuclear ri-
bonucleoproteins (snRNP) (Liu et al. 1997). Although
the consequences of genetic abnormalities in SMN are
known, a clinical phenotype from an SIP1 mutation is
unknown.
The candidate region might be narrowed down when
subject IV-3, who had been characterized as unknown
at age 3 years, eventually turns out to be affected later
in life. One recombinant event in subject IV-3 between
markers D14S1014 and D14S288 falls in the middle of
the critical region (fig. 2). The exact position of this
recombination could not be determined because the ge-
notype of this person is inconsistent with the haplotype
of the father. Because no other inconsistent genotypes
were detected, the most likely explanation is that in the
father one allele has elongated one repeat unit from 206
to 210 bases. Unfortunately, this recombination is of
little help for defining the critical region of BHC, because
the precise diagnosis of subject IV-3 is still uncertain.
Two other subjects that had been classified as un-
known (II-12 and III-8) carried the risk haplotype (fig.
2). The clinical diagnosis in II-12 was uncertain because
of a history of Sydenham chorea. However, she had an
affected daughter, which made her an obligate carrier,
and which also made the diagnosis of BHC most likely.
The second relative, III-8, might be the only case of
lowered penetrance in the family, because all other 13
clinically diagnosed relatives have the risk haplotype.
Assuming III-8 as a nonpenetrant case will still give a
nearly complete penetrance (10.90) in this family with-
out a (significant) difference between males and females.
This contrasts reports by others suggesting a lowered
penetrance in females (Harper 1978).
As shown in the current family and reported by others
(Bruyn and Myrianthopoulos 1986; Wheeler et al.
1993), there is an obvious intrafamilial variability in
BHC. Also, considerable interfamilial differences can be
observed. However, it is unknown whether this reflects
genetic heterogeneity. Further linkage studies in other
BHC families will give insight into this issue.
The improvement of choreatic movements in adoles-
cence makes the BHC an intriguing disorder. Cloning of
the BHC gene and functional studies of the BHC protein
might reveal the mechanism(s) involved in choreatic dis-
orders and the interaction of various molecular mech-
anisms in their pathogenesis.
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